1
|
Čermáková M, Pelantová H, Neprašová B, Šedivá B, Maletínská L, Kuneš J, Tomášová P, Železná B, Kuzma M. Metabolomic Study of Obesity and Its Treatment with Palmitoylated Prolactin-Releasing Peptide Analog in Spontaneously Hypertensive and Normotensive Rats. J Proteome Res 2019; 18:1735-1750. [PMID: 30810318 DOI: 10.1021/acs.jproteome.8b00964] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
In this study, the combination of metabolomics and standard biochemical and biometric parameters was used to describe the metabolic effects of diet-induced obesity and its treatment with the novel antiobesity compound palm11-PrRP31 (palmitoylated prolactin-releasing peptide) in spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY). The results showed that SHR on a high-fat (HF) diet were normoglycemic with obesity and hypertension, while WKY on the HF diet were normotensive and obese with prediabetes. NMR-based metabolomics revealed mainly several microbial cometabolites altered by the HF diet, particularly in urine. The HF diet induced similar changes in both models. However, two groups of genotype-specific metabolites were defined: metabolites specific to the genotype at baseline (e.g., 1-methylnicotinamide, phenylacetylglycine, taurine, methylamine) and metabolites reacting specifically to the HF diet in individual genotypes (2-oxoglutarate, dimethylamine, N-butyrylglycine, p-cresyl sulfate). The palm11-PrRP31 lowered body weight and improved biochemical and biometric parameters in both strains, and it improved glucose tolerance in WKY rats on the HF diet. In urine, the therapy induced significant decrease of formate and 1-methylnicotinamide in SHR and alanine, allantoin, dimethylamine, and N-butyrylglycine in WKY. Altogether, our study confirms the effectiveness of palm11-PrRP31 for antiobesity treatment.
Collapse
Affiliation(s)
- Martina Čermáková
- Faculty of Chemical Technology , University of Chemistry and Technology Prague , Technická 5 , 166 28 , Prague 6 , Czech Republic
| | | | - Barbora Neprašová
- Institute of Organic Chemistry and Biochemistry , Czech Academy of Sciences , Flemingovo nám. 2 , 166 10 , Prague 6 , Czech Republic
| | - Blanka Šedivá
- Faculty of Applied Sciences , University of West Bohemia , Univerzitní 8 , 306 14 , Plzeň , Czech Republic
| | - Lenka Maletínská
- Institute of Organic Chemistry and Biochemistry , Czech Academy of Sciences , Flemingovo nám. 2 , 166 10 , Prague 6 , Czech Republic
| | - Jaroslav Kuneš
- Institute of Organic Chemistry and Biochemistry , Czech Academy of Sciences , Flemingovo nám. 2 , 166 10 , Prague 6 , Czech Republic
| | - Petra Tomášová
- Fourth Medical Department, First Faculty of Medicine , Charles University in Prague and General University Hospital , U nemocnice 1 , 128 08 Praha 2 , Czech Republic
| | - Blanka Železná
- Institute of Organic Chemistry and Biochemistry , Czech Academy of Sciences , Flemingovo nám. 2 , 166 10 , Prague 6 , Czech Republic
| | | |
Collapse
|
2
|
Bugáňová M, Pelantová H, Holubová M, Šedivá B, Maletínská L, Železná B, Kuneš J, Kačer P, Kuzma M, Haluzík M. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. J Endocrinol 2017; 233:93-104. [PMID: 28138003 DOI: 10.1530/joe-16-0478] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Accepted: 01/30/2017] [Indexed: 01/09/2023]
Abstract
Liraglutide is the glucagon-like peptide-1 receptor agonist widely used for the treatment of type 2 diabetes mellitus. Recently, it has been demonstrated to decrease cardiovascular morbidity and mortality in patients with type 2 diabetes and high cardiovascular risk. Although the major modes of liraglutide action are well-known, its detailed action at the metabolic level has not been studied. To this end, we explored the effect of 2-week liraglutide treatment in C57BL/6 male mice with obesity and diabetes induced by 13 weeks of high-fat diet using NMR spectroscopy to capture the changes in urine metabolic profile induced by the therapy. The liraglutide treatment decreased body and fat pads weight along with blood glucose and triglyceride levels. NMR spectroscopy identified 11 metabolites significantly affected by liraglutide treatment as compared to high-fat diet-fed control group. These metabolites included ones involved in nicotinamide adenine dinucleotide metabolism, β-oxidation of fatty acids and microbiome changes. Although majority of the metabolites changed after liraglutide treatment were similar as the ones previously identified after vildagliptin administration in a similar mouse model, the changes in creatinine, taurine and trigonelline were specific for liraglutide administration. The significance of these changes and its possible use in the personalization of antidiabetic therapy in humans requires further research.
Collapse
Affiliation(s)
- Martina Bugáňová
- Institute of MicrobiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic
- Faculty of Chemical TechnologyUniversity of Chemistry and Technology Prague, Prague, Czech Republic
| | - Helena Pelantová
- Institute of MicrobiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Martina Holubová
- Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Blanka Šedivá
- Faculty of Applied SciencesUniversity of West Bohemia, Plzeň, Czech Republic
| | - Lenka Maletínská
- Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Blanka Železná
- Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Jaroslav Kuneš
- Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic
- Institute of PhysiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Petr Kačer
- Institute of MicrobiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic
- Faculty of Chemical TechnologyUniversity of Chemistry and Technology Prague, Prague, Czech Republic
| | - Marek Kuzma
- Institute of MicrobiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Martin Haluzík
- Centre for Experimental Medicine and Diabetes CentreInstitute for Clinical and Experimental Medicine, Prague, Czech Republic
- Institute of Medical Biochemistry and Laboratory Diagnostics1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| |
Collapse
|
3
|
Timbrell JA, Waterfield CJ. Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1996; 403:125-34. [PMID: 8915350 DOI: 10.1007/978-1-4899-0182-8_15] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We have shown that urinary taurine level may be used as a biomarker of pathological and biochemical lesions. Detection of changes in the urinary concentration of this low molecular weight metabolite indicates biochemical lesions which may also be associated with pathological damage. Hepatotoxic compounds such as CCl4, galactosamine and thioacetamide that cause hepatic necrosis and compounds such as hydrazine and ethionine that cause fatty liver all result in elevated urinary taurine levels in rats. However compounds which do not cause liver damage, such as cycloheximide, also raise urinary taurine levels. All of these substances are known to or are believed to inhibit protein synthesis. Conversely, compounds which increase protein synthesis, such as phenobarbital and clenbuterol, significantly decrease urinary taurine levels. Compounds which interfere with hepatic GSH synthesis will also change urinary taurine levels. Thus, depletion of GSH with diethyl maleate or phorone decreases urinary taurine whereas inhibition of GSH synthesis with compounds such as buthionine sulphoximine increases urinary taurine levels. In isolated hepatocytes in vitro, leakage of taurine occurs in response to cytotoxic compounds such as hydrazine and allyl alcohol. However, total taurine levels were increased by the hepatotoxicant CCl4. Taurine synthesis is decreased by depletion of GSH with allyl alcohol in isolated hepatocytes. Therefore taurine levels are an important potential biomarker for biochemical lesions induced by chemicals both in vivo and in vitro, in particular changes in protein and GSH synthesis.
Collapse
Affiliation(s)
- J A Timbrell
- Toxicology Department, School of Pharmacy, London, United Kingdom
| | | |
Collapse
|
4
|
Timbrell JA, Seabra V, Waterfield CJ. The in vivo and in vitro protective properties of taurine. GENERAL PHARMACOLOGY 1995; 26:453-62. [PMID: 7789717 DOI: 10.1016/0306-3623(94)00203-y] [Citation(s) in RCA: 196] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
1. Taurine is a ubiquitous, free amino acid found in mammalian systems. 2. The biological functions of taurine are unclear. 3. Various in vivo data suggest that taurine has a variety of protective functions and deficiency leads to pathological changes. 4. Depletion in rats of taurine increases susceptibility to liver damage from carbon tetrachloride. 5. Susceptibility to a variety of hepatotoxicants correlates with the estimated hepatic taurine level. 6. In vitro data suggest that taurine can protect cells against toxic damage. 7. Taurine protects isolated hepatocytes against carbon tetrachloride, hydrazine and 1,4-naphthoquinone but not against allyl alcohol, alpha-naphthylisothiocyanate (ANIT) or diaminodiphenyl methane (DAPM) cytotoxicity. 8. The mechanisms of protection are unclear but may include modulation of calcium levels, osmoregulation and membrane stabilization.
Collapse
Affiliation(s)
- J A Timbrell
- Toxicology Department, School of Pharmacy, London, U.K
| | | | | |
Collapse
|
5
|
Waterfield CJ, Turton JA, Scales MD, Timbrell JA. Taurine, a possible urinary marker of liver damage: a study of taurine excretion in carbon tetrachloride-treated rats. Arch Toxicol 1991; 65:548-55. [PMID: 1685880 DOI: 10.1007/bf01973715] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Carbon tetrachloride (CCl4) caused a dose-dependent increase in urinary taurine which correlated with both the histological and biochemical assessment of liver damage. The peak elevation in urinary taurine occurred within the first 48 h after dosing but there was still significant taurinuria 72 and 96 h after the intermediate dose (1 ml.kg-1) and highest dose (2 ml.kg-1), respectively. Levels of taurine in serum were also elevated over the 24 h period following a hepatotoxic dose (2 ml.kg-1) of CCl4. In contrast, although initially elevated, levels of taurine in the liver declined over the 24 h period following dosing and were significantly lower 96 h after a hepatotoxic dose of CCl4 (2 ml.kg-1). Male rats showed a different urinary profile for taurine than female rats after dosing with CCl4. A reduction in food intake seemed to lower urinary taurine levels although these changes were not statistically significant. There was a significant correlation between the level of urinary taurine and the level of serum AST for individual animals given a hepatotoxic dose of CCl4 (2 ml.kg-1). The data presented suggest that: i) taurine is produced by the liver in response to a toxic insult and subsequent leakage from damaged cells leads to increased levels in the urine; ii) the urinary taurine level may be a useful non-invasive marker of liver damage.
Collapse
Affiliation(s)
- C J Waterfield
- Toxicology Unit, School of Pharmacy, University of London, UK
| | | | | | | |
Collapse
|